Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05491005

The eHealth Diabetes Remission Trial

Overweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy control group with normal glucose tolerance is examined once but is not randomised and does not receive any intervention.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bra Liv Råslätt vårdcentral, Jönköping, Sweden

Loading trial locations.

About this study

One hundred and six overweight patients with type 2 diabetes replace usual foods with total diet replacement (850 kcal/day) for 3 months with the goal of 15 kg weight loss and diabetes remission (HbA1c < 48 mmol/mol without diabetes medication). After 3 months of total diet replacement, food is reintroduced stepwise, and an individually tailored energy prescription is used to prevent weight regain. If study participants do not reach the weight loss goal at 3 months, they are recommended two additional months of total diet replacement. If weight regain occurs during the weight maintenance phase, a rescue plan with total diet replacement will be recommended. To increase the chances to maintain their lower body weight, participants will use a program specifically design for that purpose based on cognitive behavioural therapy. Total study duration is two years.

The one hundred and six participants are randomised to either the eHealth follow-up or the face-to-face follow-up. The dietary advice to achieve and maintain weight loss is the same in both groups and delivered by the same dietician, physician, and nurse but the method of follow-up differs between groups (eHealth vs face-to-face).

eHealth group:

All study information and the cognitive behavioural therapy program is given by an eHealth application in Stöd och behandling which is part of 1177.se. Participants register body weight, fasting blood glucose, and blood pressure every morning at 1177.se. Regularly a measurement of HbA1c is taken at home. Participants will have scheduled video appointments with the study dietician, study nurse or study physician.

Face-to-face group:

Participants have appointments in the medical office with the study physician/nurse/dietician. At the appointments, body weight, blood pressure and capillary blood glucose is measured. HbA1c is measured during the appointments at 0, 6, 12 and 24 months. The cognitive behavioral therapy program for the control group is identical to the program of the intervention group, but the program is delivered during the face-to-face appointments.

Healthy control group:

Fifteen healthy participants with normal glucose tolerance, stable body weight for at least one year and matched to the study participants for sex, age, and weight after one year study duration, will be examined once. These participants are not randomised and do not receive any intervention.

Outcomes:

Primary and secondary outcome measures are compared between 1) the experimental eHealth group and 2) the experimental face-to-face group. For the other pre-specified outcome measures the experimental eHealth group and the experimental face-to-face group are taken together as one group, examined twice (baseline and 12 months) and compared to the healthy control group, that is examined only once.

Long-term follow-up:

Because long term data on diabetes remission by total diet replacement are lacking, study participants will be followed after they have finished the study. Data of the national diabetes registry from participants of this study will be compared to other patients in the national diabetes registry not participating in this study but matched for age, sex and diabetes duration to the study participants.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes with duration 0-6 years
  • BMI 27 kg/m2 and higher
  • HbA1c 43 mmol/mol or higher (48 or higher if without diabetes medication)

Exclusion criteria

  • Insulin treatment
  • Weight loss more than 5 kg during the past 6 months
  • Diagnosed eating disorder
  • eGFR < 30 ml/min/1,73m2
  • Myocardial infarction last six months
  • Severe heart failure (NYHA class III)
  • Ongoing cancer
  • Pregnancy
  • Treatment with antipsychotic drugs

Treatment and study plan

Total diet replacement

Behavioral

Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.

eHealth

Behavioral

All follow-up through an eHealth application and video meetings.

Face-to-face

Behavioral

All follow-up through face-to-face meetings.

Primary outcomes

  1. HbA1c

    Time frame: 12 months

    HbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.

Secondary outcomes

  1. HbA1c

    Time frame: 6 and 24 months

    HbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.

  2. Diabetes remission

    Time frame: 6, 12 and 24 months

    Number of participants with HbA1c < 48 mmol/mol without diabetes medication. The outcome will be tested for non-inferiority first with a non-inferiority margin of 10 percentage points; followed by a test for superiority.

  3. Body weight

    Time frame: 6, 12 and 24 months

    Body weight as a continuous outcome

  4. Achieved weight loss of at least 15 kg

    Time frame: 6, 12 and 24 months

    Number of participants with achieved weight loss of at least 15 kg

  5. Incremental costs per diabetes remission

    Time frame: 24 months

  6. Estimated lifetime costs

    Time frame: 24 months

  7. Estimated lifetime costs per quality-adjusted life-year (QALY)

    Time frame: 24 months

  8. Fasting blood glucose

    Time frame: 6, 12, 24 months

    Partial diabetes remission (<7.0 mol/l), complete diabetes remission (<6.1 mol/l) without diabetes medication.

  9. P-glucose 120 minutes after the oral glucose tolerance test

    Time frame: 6, 12, 24 months

  10. Number of prescribed oral anti diabetic medications

    Time frame: 6, 12, 24 months

  11. Number of prescribed antihypertensive medications

    Time frame: 6, 12, 24 months

  12. Blood pressure (systolic/diastolic)

    Time frame: 6, 12, 24 months

    Measured at the research facilities

  13. Blood pressure

    Time frame: 6, 12, 24 months

    24h monitoring

  14. Plasma lipid profile

    Time frame: 6, 12, 24 months

  15. Liver enzymes

    Time frame: 6, 12, 24 months

    AST, ALT

  16. Number of participants that discontinue the intervention

    Time frame: 6, 12, 24 months

  17. Waist circumference

    Time frame: 6, 12, 24 months

  18. Relation to food

    Time frame: 6, 12, 24 months

    Three factor eating questionnaire

  19. Estimation of exhaustion

    Time frame: 6, 12, 24 months

    Karolinska Exhaustion Disorder Scale. Minimum value 0. Maximum value 54. A higher score means a worse outcome.

  20. Quality of life accoring to Brunnsviken Brief Quality of Life Scale

    Time frame: 6, 12, 24 months

    The scale estimates how satisfied the participants is with different areas of life, as well as how important each area of life is. Minimum scale 0. Maximum scale 48. A higher score means a better outcome.

  21. Quality of life according to EQ-5D-5L

    Time frame: 6, 12, 24 months

    The questionnaire investigates the dimensions mobility, self-care, usual activities, pain and anxiety/depression. Minimum value 1. Maximum value 5. A higher score means a worse outcome. In addition, a general health score is assessed. Minimum value 0. Maximum value 100. A higher score means a better outcome. All dimension will be analysed separately, but EQ-5D-5L will also be combined to one score.

  22. Eating habits

    Time frame: 6, 12, 24 months

    FFQ 2020 questionnaire

  23. Estimation of health

    Time frame: 6, 12, 24 months

    SF-36 questionnaire

  24. Daily steps

    Time frame: 6, 12, 24 months

    Measured with activity tracker

  25. Study experience

    Time frame: 24 months

    Qualitative questions with written answers about study experience

  26. HbA1c follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals after study completion

  27. Body weight follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals after study completion

  28. Blood pressure follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals after study completion

  29. Usage of diabetes medication follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals after study completion

  30. Usage of hypertension medication follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals after study completion

  31. Diabetes complications follow-up

    Time frame: Yearly up to 20 years

    Collected from patient journals and registries after study completion

Other outcomes

  1. Insulin sensitivity

    Time frame: 12 months

    Hyperinsulinemic euglycemic clamp

  2. Insulin secretion

    Time frame: 12 months

    Stepped insulin secretion test with arginine

  3. Metabolic flexibility

    Time frame: 12 months

    Hyperinsulinemic euglycemic clamp

  4. Resting metabolic rate

    Time frame: 12 months

    Indirect calorimetry

  5. Body composition

    Time frame: 12 months

    Dual-energy X-ray absorptiometry (DXA).

  6. Glucagon sensitivity

    Time frame: 12 months

    Plasma amino acids are measured during 120 minutes after a intravenous glucagon bolus

  7. Amino acid tolerance

    Time frame: 12 months

    Plasma amino acids are measured during intravenous amino acid infusion

  8. Glucagon secretion capacity

    Time frame: 12 months

    Plasma glucagon is measured during intravenous amino acid infusion

  9. Gut hormones after carbohydrate intake

    Time frame: 6, 12, 24 months

    GLP-1, GIP and gherkin during the oral glucose tolerance test

  10. P-metabolites and P-lipids after carbohydrate intake

    Time frame: 6, 12, 24 months

    Metabolomics and lipidomics analyses during the oral glucose tolerance test

  11. Liver fat

    Time frame: 12 months

    Measured with MRI

  12. Pancreas fat

    Time frame: 12 months

    Measured with MRI

  13. Fat cell size in subcutaneous fat

    Time frame: 12 months

  14. RNA levels in subcutaneous fat

    Time frame: 12 months

    RNA sequencing

  15. Secretion of adipokines, metabolites and lipids in subcutaneous fat cells ex vivo

    Time frame: 12 months

  16. Plasma testosterone levels

    Time frame: 6, 12 and 24 months

    Only men

  17. Erectile function

    Time frame: 6, 12, 24 months

    Only men, Erectile function subscale

  18. Prostate symptoms

    Time frame: 6, 12, 24 months

    Only men, International prostate symptom score

  19. Urine albumin to creatinine ratio

    Time frame: 6, 12, 24 months

  20. Slow vital capacity (SVC)

    Time frame: 12 months

    Spirometry

  21. Forced vital capacity (FVC)

    Time frame: 12 months

    Spirometry

  22. Forced expiratory volume in 1 s (FEV1)

    Time frame: 12 months

    Spirometry

  23. Diffusion capacity of the the (DCLO)

    Time frame: 12 months

    Spirometry

  24. Experiences of the study participants

    Time frame: Once between 12 and 24 months

    Individual semi-structured interviews

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Otten, PhD

CONTACT

[email protected]

+46703341559

Sponsors and collaborators

Lead sponsor

Umeå University

Other

Collaborators

  • Edgar Sjölunds Diabetes Foundation
  • Region Västerbotten

Registry information

Official study title

eHealth Diabetes Remission Trial (Swedish: Remission av Typ 2 Diabetes Med hjälp av eHälsa

Acronym: eDIT

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Aug 8, 2022
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.